menu
    • menu
    [{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"UMDF","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Khondrion \/ UMDF","highestDevelopmentStatusID":"10","companyTruncated":"Khondrion \/ UMDF"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Khondrion

    Menu

    Khondrion

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : UMDF

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            UMDF Supports Khondrion Drug Development for Primary Mitochondrial Disease

                            Details : The proceeds will be used for the development of KH176 (sonlicromanol), a first-in-class, brain-penetrant redox-modulator, for adults with primary mitochondrial disease due to the m.3243A>G mutation.

                            Product Name : KH176

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : UMDF

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Khondrion Gets FDA Clearance for Sonlicromanol Phase 3 in Mitochondrial Disease

                            Details : KH176 (sonlicromanol) is a mPGES-1 inhibitor small molecule drug candidate, which is being evaluated for the treatment of adult patients with PMD due to the m.3243A>G mutation.

                            Product Name : KH176

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Khondrion Announces Sonlicromanol Phase IIb Progress Supporting Phase III Development in Melas Spectrum Disord...

                            Details : Patients treated with KH176 (sonlicromanol) for 28 days did not achieve statistically significant improvement in attention domain score of cognitive functioning, as assessed by the computerised Cogstate visual identification test, compared to those who r...

                            Product Name : KH176

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 22, 2022

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Khondrion Completes Enrolment in KHENERGYZE Phase IIb Trial Evaluating Sonlicromanol in Adult Patients With ME...

                            Details : Topline data from KHENERGYZE Phase IIb trial for KH176 (sonlicromanol) is expected in the third quarter of 2022, Phase IIa study showed a significant improvement in attention and mood-related outcomes in patients with MELAS spectrum disorder.

                            Product Name : KH176

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 01, 2022

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Khondrion Receives EMA Agreement on its Paediatric Investigation Plan for Sonlicromanol

                            Details : With the acceptance of the PIP, Khondrion plans to initiate a paediatric trial to evaluate the safety and efficacy of sonlicromanol in children from birth to less than 18 years with mitochondrial disease affecting oxidative phosphorylation and symptoms o...

                            Product Name : KH176

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 18, 2021

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Khondrion Shares Progress of Sonlicromanol Development Programme at Mitochondrial Medicine 2020 Virtual Confer...

                            Details : An ongoing Phase 2B clinical trial in patients with MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) spectrum disorders is investigating the effect of sonlicromanol on cognitive functioning.

                            Product Name : KH176

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 27, 2020

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Khondrion Highlights Potential Role Of Inflammatory Lipid Modulator Prostaglandin E2 In COVID-19 Disease And P...

                            Details : Company’s lead asset sonlicromanol may have potential as a repurposed treatment for PGE2-driven inflammatory consequences underlying severe COVID-19 disease.

                            Product Name : KH176

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 15, 2020

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed

                            Khondrion

                            Netherlands arrow
                            World Vaccine Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases

                            Details : The study’s primary objective is to evaluate the dose-effect of Sonlicromanol on the attention domain score of cognitive functioning, Results are expected in the second half of 2020.

                            Product Name : KH176

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 27, 2020

                            Lead Product(s) : Sonlicromanol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth